Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Employees

Sector

Biotechnology & Medical Research

Calendar

07-29 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	US$13.55	-0.37%	54,940
23/07/26	US$13.60	-0.80%	42,099
22/07/26	US$13.71	-1.58%	46,762
21/07/26	US$13.93	+2.43%	57,398
20/07/26	US$13.60	-2.44%	73,632

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

13.55USD

Average target price

12.00USD

Spread / Average Target

-11.44%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 24/07/2026 BST			5-day change	1st Jan Change
13.55 ^USD	-0.37%		-2.80%	-2.90%

07-02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
06-30	Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	CI

Market Cap	284M 250M 232M 213M 400M 27.36B 406M 2.76B 1.08B 13.45B 1.07B 1.04B 46.51B	P/E 2026 *	-452x	P/E 2027 *	-678x
Enterprise Value	110M 96.85M 90.06M 82.65M 155M 10.62B 158M 1.07B 418M 5.22B 414M 405M 18.05B	EV / Sales 2026 *	0.62x	EV / Sales 2027 *	0.61x
Free-Float	89.38%	Yield 2026 *	-	Yield 2027 *	-

07-02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
06-30	Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	CI
06-29	European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading	MT
06-23	Top cases on the US Supreme Court's docket	RE
06-22	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
06-18	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT
06-09	European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading	MT
06-08	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT
06-05	The Jobs Report Just Made the Fed's Life Harder
06-05	To infinity and beyond
06-04	Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case	MT
06-04	Top cases on the US Supreme Court's docket	RE
06-04	Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case	MT

27/10/25	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25/06/25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
25/10/23	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
19/07/23	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
06/01/23	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT

Amarin Corporation plc Share Price

Stocks

AMRN

US0231114044

Biotechnology & Medical Research

Valuation: Amarin Corporation plc

Chart: Amarin Corporation plc

Latest news : Amarin Corporation plc

Last Transcript: Amarin Corporation plc

Analysts' recommendations: Amarin Corporation plc

Press Releases: Amarin Corporation plc

News in other languages: Amarin Corporation plc

Quotes and Performance

Course Extremes

Managers and Directors: Amarin Corporation plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-15	Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026	AQ
06-30	Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	AQ
05-27	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia	AQ
04-29	Amarin: Q1 Earnings Snapshot	AQ
04-29	Amarin Reports 2026 First Quarter Financial Results	AQ

06-05	Afternoon Meeting: Los datos de empleo complican la labor de la Fed
06-05	Bourse : Lululemon dévisse, Blackstone se protège, Schneider émet 850 MEUR d'OCEANE
29/07/25	Recordati : firmato contratto di licenza e fornitura con Amarin per 25mln $ (RCO)
24/06/25	Recordati e Amarin commercializzano il farmaco cardiovascolare Vazkepa
29/03/22	Amarin reçoit un remboursement pour VAZKEPA® en Suède

1 day	-0.37%
1 week	-2.80%
Current month	-14.99%
1 month	-17.43%
3 months	-5.31%
6 months	-16.67%
Current year	-2.90%

1 week	13.47	14.34
1 month	13.47	16.79
Current year	12.96	17.31
1 year	12.96	20.9
3 years	7.08	27.4
5 years	7.08	119.4
10 years	7.08	522.4

Manager	Title	Age	Since
Aaron Berg CEO	Chief Executive Officer	63	03/06/2024
Peter Fishman DFI	Director of Finance/CFO	42	22/10/2024
Jonathan Provoost CMP	Compliance Officer	56	14/11/2023

Director	Title	Age	Since
Aaron Berg BRD	Director/Board Member	63	03/06/2024
Louis Sterling BRD	Director/Board Member	47	27/02/2023
Odysseas Kostas CHM	Chairman	51	26/03/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/07/26	Peter Fishman	Fiscal year	Chief Financial Officer	6,100	0.0015%
01/07/26	Steven Ketchum	Fiscal year	Chief Technology Officer	9,263	0.0022%
01/07/26	David Keenan	Fiscal year	Chief Operating Officer	9,302	0.0022%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMARIN CORPORATION PLC	-0.37%	-2.80%	-12.58%	-41.59%	284M
ARGENX SE	+0.93%	+6.97%	+62.83%	+67.97%	57.28B
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+43.68%	+84.56%	54.99B
INSMED INCORPORATED	-0.46%	-1.29%	+3.28%	+422.58%	23.18B
BIONTECH SE	-2.97%	-2.35%	-22.03%	-16.54%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+5.73%	+30.99%	-3.58%	20.46B
GENMAB A/S	-1.34%	+0.51%	+25.02%	-30.27%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	+5.67%	+32.54%	+544.11%	15.67B
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+165.62%	+291.37%	14.46B
EXELIXIS, INC.	-0.50%	-0.98%	+23.62%	+178.38%	13.92B
Average	-0.97%	+0.87%	+35.30%	+149.70%	24.04B
Weighted average by Cap.	-0.87%	+2.09%	+41.11%	+135.48%

	2026 *	2027 *
Net sales	178M 156M 145M 133M 250M 17.12B 254M 1.72B 674M 8.42B 667M 653M 29.1B	159M 139M 130M 119M 224M 15.3B 227M 1.54B 602M 7.52B 596M 583M 26B
Net income	-12.75M -11.19M -10.41M -9.55M -17.95M -1.23B -18.23M -124M -48.3M -603M -47.85M -46.82M -2.09B	-9.04M -7.94M -7.38M -6.77M -12.73M -870M -12.92M -87.66M -34.25M -428M -33.93M -33.2M -1.48B
Net Debt	-174M -153M -142M -130M -245M -16.74B -249M -1.69B -659M -8.23B -653M -639M -28.46B	-187M -165M -153M -141M -264M -18.06B -268M -1.82B -710M -8.88B -704M -689M -30.69B